Our Passion for IPOs
News & Views
Largest Global IPOs
Largest US IPOs
Largest US IPOs YTD
Largest US Internet IPOs
Top First Day Returns
US IPO Stats
IPO Average Age
IPO Industry Breakdown
Offer Price Discounts
Global IPO Stats
IPOs by Region
IPO Industry Breakdown
2012 US IPO Review
2012 Global IPO Review
3Q US IPO Review
3Q Global IPO Review
Press Contact Form
Free iPhone App
Free Android App
IPO News Feed
IPO News Archive
Interested in IPO Investing?
AVEO Pharmaceuticals announces terms for $98 million IPO
AVEO Pharmaceuticals, which is developing novel cancer therapeutics and planning a Phase 3 trial for its lead candidate tivozanib, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $98 million by offering 7 million shares at a price range of $13-$15. At the mid-point of the proposed range, the biotech will command a market value of $387 million. AVEO, which was founded in 2001, has generated roughly $170 million in revenue from strategic partnerships with Merck, OSI and Biogen Idec: $92 million from license fees, milestone payments and R&D funding and an additional $80 million in equity financing. Notable venture backers include MPM Capital (11%), Highland Capital Partners (10%), Venrock (8%) and Prospect Venture Partners (8%). AVEO's filing comes only three weeks after the listing of another Boston-based biotech, Ironwood Pharmaceuticals, which was the biggest biotech IPO in nearly eight years. AVEO plans to list on the NASDAQ under the symbol AVEO; IPO proceeds will be used to fund the Phase 3 clinical trial for tivozanib, for which commercialization is tentatively scheduled for 2013. J.P. Morgan and Morgan Stanley are the lead underwriters on the deal. Timing was not disclosed.
Keywords / Tickers:
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included:
IPO investment firm Renaissance Capital (www.renaissancecapital.com)
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Global IPO Fund (symbol: IPOSX) or the Renaissance IPO ETF (symbol: IPO), may have investments in securities of companies mentioned.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Net Asset Value (NAV)
of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding.
is current value at which an asset or service can be bought or sold.
is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
The S&P 500® Index (SPX)
is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE. The S&P 500 index components are determined by S&P Dow Jones Indices.
The Russell 3000® Index (RAY)
is a stock market index of US stocks which measures the performance of 3,000 publicly held US companies based on total market capitalization. The Russell 3000 index components are determined by Russell Investments.
Investments in the
Renaissance IPO ETF, symbol "IPO"
(the “ETF”) and the
Global IPO Fund, symbol "IPOSX"
(the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETF and the Mutual Fund (the “Funds”) invest in companies that have recently completed their initial public offerings. These stocks may be subject to extreme price volatility and speculative trading. The Funds may also be subject to information technology risk, small and mid-capitalization company risk, REIT risk, Master Limited Partnership (MLP) risk, non-U.S. issuer risk and replication management risk. ETF returns may not match the return of the respective index. The ETF is classified as a non-diversified investment company and is subject to concentration risk. Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus with information about the Funds please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETF, 1-866-486-6645.
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2013 Renaissance Capital LLC. All rights reserved.